The benefit of double vaccination “is very high for Sputnik, Astra Zeneca or Sinopharm, which prevent 90% of the risk of hospitalizations.
–
The Minister of Health of the City of Buenos Aires, Fernn Quirs, assured that according to a study on the interchangeability of vaccines in the City that be published in a scientific journal in the next few daysBoth the Astra Zeneca, Moderna or Sputnik 1 vaccines increase antibodies by at least three, while Sinopharm does not achieve that increase.
The advance of the study, carried out on 800,000 portages in the pre-Delta stage, was disseminated by the holder of the port health portfolio during the 24th Argentine Health Congress organized by the Civil Association of Medical Activities (Acami).
“We all know that Sinopharm has a greater impact on cellular immunity, not on the amount of antibodies” Quirs noted and noted that the vaccines of “Astra Zeneca and Moderna give a very significant response, similar to Sputnik. Astra Zeneca a little less than Sputnik 2 and Moderna twice as much as Sputnik 2”.
The official detailed, in addition to “The combination of a viral vector vaccine with a messenger RNA vaccine is the best combination, even more so than the homologous schemes. Our results are quite conclusive, the vaccine that most arouses antibodies is a vaccine like Sputnik in the first component and one of Moderna in the second component “.
On the other hand, he stressed that according to the same study the benefit of double vaccination “It is very high both for Sputnik, as Astra Zeneca or Sinopharm, which 90% prevent the risk of hospitalization. Always Sputnik at the top, Astra Zeneca intermediate and Sinopharm a little lower. “
Quirs stressed that next month “when we receive the vaccine from Pfizer we will begin immunizing children between the ages of 12 and 17” and that first “we still need to vaccinate some 600,000 porters who still do not have the two doses applied, which we will do this month.”
Regarding a possible third dose, Quirs remarked that “we are still not entirely sure” of applying it since the evidence in other countries “is not conclusive” and pointed out that he hopes to finish the vaccination schedule with two doses by the end of November and in December analyze the possibility of a third.
For Quirs the non-acceptance in Europe of people who have the Sputnik vaccine is due to “a geopolitical rather than a health issue” and he stressed that in the pandemic “the countries did not act in a coordinated manner but each one sought their own response and that is why we had the distribution of vaccines as we had.”
– .
